文献速递白血病

接受维奈克拉联合低甲基化药物治疗的急性髓系白血病患者感染特征分析

Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
PubMed 文献 · Br J Haematol · 2022-02-16

这项回顾性多中心队列研究纳入2016年1月至2020年8月期间接受至少一个周期维奈克拉联合阿扎胞苷或地西他滨治疗的成人急性髓系白血病患者,主要结局为可能或确诊侵袭性真菌感染的发生率。235例患者中,可能或确诊侵袭性真菌感染发生率为5.1%,至少一次细菌感染发生率为33.6%,127例(54%)患者至少一次因中性粒细胞缺乏伴发热住院。

要点

  • 可能或确诊侵袭性真菌感染发生率为5.1%,在不同年龄、抗真菌预防用药或疾病状态间无显著差异。
  • 在可能或确诊侵袭性真菌感染亚组中,6例(50%)感染时正在接受抗真菌预防。
  • 至少一次细菌感染发生率为33.6%,127例(54%)患者至少一次因中性粒细胞缺乏伴发热住院。

核心结论

  • 本研究显示可能或确诊侵袭性真菌感染总体风险较低,同时记录了相当比例的细菌感染和因中性粒细胞缺乏伴发热住院。

研究设计与样本

  • 回顾性、多中心队列研究,纳入2016年1月至2020年8月期间接受至少一个周期维奈克拉联合阿扎胞苷或地西他滨治疗的成人急性髓系白血病患者,共235例。

主要发现

  • 235例患者中,可能或确诊侵袭性真菌感染发生率为5.1%。
  • 侵袭性真菌感染发生率按年龄、抗真菌预防用药或疾病状态比较均无显著差异。
  • 在可能或确诊侵袭性真菌感染亚组中,6例(50%)在感染时正在接受抗真菌预防。
  • 至少一次细菌感染的总发生率为33.6%,127例(54%)患者至少一次因中性粒细胞缺乏伴发热住院。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We investigated the incidence of invasive fungal infections (IFIs) and other infectious complications in patients receiving venetoclax and hypomethylating agent therapy for acute myeloid leukaemia (AML). This retrospective, multicentre cohort study included adult patients with AML who received at least one cycle of venetoclax and either azacitidine or decitabine between January 2016 and August 2020. The primary outcome was the incidence of probable or confirmed IFI. Secondary outcomes included antifungal prophylaxis prescribing patterns, incidence of bacterial infections, and incidence of neutropenic fever hospital admissions. Among 235 patients, the incidence of probable or confirmed IFI was 5.1%. IFI incidence did not differ significantly according to age, antifungal prophylaxis use, or disease status. In the subgroup of patients with probable or confirmed IFIs, six (50%) were receiving antifungal prophylaxis at the time of infection. The overall incidence of developing at least one bacterial infection was 33.6% and 127 (54%) patients had at least one hospital admission for febrile neutropenia. This study demonstrated an overall low risk of developing probable or confirmed IFI as well as a notable percentage of documented bacterial infections and hospital admissions due to neutropenic fever.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. On S, Rath CG, Lan M, et al. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. Br J Haematol. 2022. PMID: 35174480. doi:10.1111/bjh.18051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。